References
- Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006; 291: C1208–12
- Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006; 97: 52C–60C
- Zipp F, Waiczies S, Aktas O, Neuhaus O, Hemmer B, Schraven B, et al. Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci. 2007; 28: 342–9
- Borghi C, Modugno GC, Pirodda A. Possible role of HMG-CoA reductase inhibitors for the treatment of sudden sensorineural hearing loss (SSHL). Med Hypotheses 2002; 58: 399–402
- Tavintharan S, Ong CN, Jeyaseelan K, Sivakumar M, Lim SC, Sum CF. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity?. Toxicol Appl Pharmacol. 2007; 223: 173–9
- Davidson MH, Stein EA, Dujovne CA, Hunninghake DB, Weiss SR, Knopp RH, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 1997; 79: 38–42
- Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004; 116: 408–16
- Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996; 2: 483–91
- de Langen JJ, van Puijenbroek EP. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. Neth J Med. 2006; 64: 334–8
- García-Román N, Alvarez AM, Toro MJ, Montes A, Lorenzo MJ. Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Mol Cell Neurosci. 2001; 17: 329–41
- Schulz JG, Bösel J, Stoeckel M, Megow D, Dirnagl U, Endres M. HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem. 2004; 89: 24–32
- Gaist D, Jeppesen U, Andersen M, García Rodríguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58: 1333–7
- Nicholl AJ, Kneebone A, Davies D, Cacciabue-Rivolta DI, Rivolta MN, Coffey P, et al. Differentiation of an auditory neuronal cell line suitable for cell transplantation. Eur J Neurosci. 2005; 22: 343–53
- Zhao J, Mao Y, Qi J. Expression of cytoskeleton and apoptosis related genes after cerebral infarction. Neurol Res. 2006; 28: 71–5
- Koch G, Benz C, Schmidt G, Olenik C, Aktories K. Role of Rho protein in lovastatin-induced breakdown of actin cytoskeleton. J Pharmacol Exp Ther. 1997; 283: 901–9
- Holmberg E, Nordstrom T, Gross M, Kluge B, Zhang SX, Doolen S. Simvastatin promotes neurite outgrowth in the presence of inhibitory molecules found in central nervous system injury. J Neurotrauma 2006; 23: 1366–78
- Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1996; 60: 54–61
- Syka J, Ouda L, Nachtigal P, Solichová D, Semecký V. Atorvastatin slows down the deterioration of inner ear function with age in mice. Neurosci Lett. 2007; 411: 112–6
- Olzowy B, Canis M, Hempel JM, Mazurek B, Suckfüll M. Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: results of a prospective, randomized, double-blind clinical trial. Otol Neurotol. 2007; 28: 455–8
- Cadoni G, Scipione S, Agostino S, Addolorato G, Cianfrone F, Leggio L, et al. Coenzyme Q 10 and cardiovascular risk factors in idiopathic sudden sensorineural hearing loss patients. Otol Neurotol. 2007; 28: 878–83